This prospective observational cohort study aims to evaluate the predictive value of interleukin-6 (IL-6) levels and hemogram-derived inflammatory scores for morbidity and in-hospital mortality in postoperative patients admitted to the intensive care unit (ICU). IL-6 levels and inflammatory indices will be assessed at ICU admission and at 24 hours using data obtained from routine clinical care. Associations between these biomarkers and clinical outcomes, including mortality, morbidity, antibiotic use, and duration of mechanical ventilation, will be evaluated after adjustment for illness severity.
This prospective observational cohort study will include adult postoperative patients admitted to the intensive care unit (ICU). The study is purely observational, and no additional interventions or procedures will be performed beyond routine clinical care. Interleukin-6 (IL-6) levels will be recorded at ICU admission (0 hour) and at 24 hours. Routine laboratory parameters obtained during standard clinical follow-up, including complete blood count, C-reactive protein (CRP), and albumin levels, will be used to calculate hemogram-derived inflammatory indices such as the neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), systemic immune-inflammation index (SII), systemic inflammation response index (SIRI), neutrophil-to-monocyte ratio (NMR), CRP-to-albumin ratio (CAR), CRP-to-lymphocyte ratio (CLR), and the modified systemic inflammation score (mSIS). Illness severity and comorbidity burden will be assessed using established scoring systems, including the Acute Physiology and Chronic Health Evaluation II (APACHE II), Sequential Organ Failure Assessment (SOFA), and the Charlson Comorbidity Index. Demographic characteristics, surgical variables (type and duration of surgery), and clinical outcomes will be prospectively recorded. The primary objective is to evaluate the predictive value of IL-6 levels and inflammatory indices for in-hospital mortality. Secondary objectives include associations with postoperative morbidity, infectious complications, antibiotic use, duration of mechanical ventilation, organ dysfunction, and ICU length of stay. Changes in IL-6 levels and inflammatory indices between ICU admission and 24 hours will also be explored.
Study Type
OBSERVATIONAL
Enrollment
42
Recep Erin
Trabzon, Turkey (Türkiye)
RECRUITINGIn-hospital mortality (all-cause)
In-hospital all-cause mortality within 28 days of intensive care unit admission, assessed using routinely collected clinical data.
Time frame: Within 28 days of ICU admission
Postoperative morbidity
Postoperative morbidity within 28 days of intensive care unit admission. Postoperative morbidity includes sepsis defined according to Sepsis-3 criteria and acute kidney injury defined according to KDIGO criteria, assessed using routinely collected clinical data.
Time frame: Within 28 days
Antibiotic use
Use of systemic antibiotic therapy during the hospital stay, assessed within 28 days of intensive care unit admission using routinely recorded clinical data.
Time frame: Within 28 days
Duration of mechanical ventilation
Duration of invasive mechanical ventilation, measured as total number of days of ventilatory support within 28 days following intensive care unit admission.
Time frame: Within 28 days
ICU length of stay
Length of stay in the intensive care unit, defined as the number of days from ICU admission to ICU discharge.
Time frame: Within 28 days
Infectious complications / sepsis
Development of infectious complications, including sepsis defined according to Sepsis-3 criteria, during the hospital stay within 28 days of ICU admission.
Time frame: Within 28 days
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.